Superworth

Scinai Immunotherapeutics SCNI

Biotechnology, Healthcare
$0.47
+0.55%
Market cap
$657.9M
PE
n/m
not a meaningful number
Forward PE
n/m
not a meaningful number
Price to sales
n/m
not a meaningful number
EV/EBIT
n/m
not a meaningful number
Revenue, 12 months
n/m
not a meaningful number
Net margin
n/m
not a meaningful number
Free cash flow yield
n/m
not a meaningful number

Charts

Financials

Income statement for SCNI, by quarter
Income statementQ1 FY22Q1 FY23
R&D$1.2M$2M
SG&A$1.5M$1.2M
−$2.6M−$3.2M
Net income−$2.5M−$3.5M
$0.00$0.00
7.4M13M

EPS, diluted: Q1 FY22 and Q1 FY23: quarter's net income to common over its shares, to the cent.

From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.

Peers

Companies in Biotechnology nearest Scinai Immunotherapeutics' size, closest first.

CompanyMarket capPEIts 10y median PEFwd PEP/SRevenue growthNet margin
SCNIScinai Immunotherapeutics$657.9Mn/mn/an/mn/mn/m
MGTXMeiraGTx$895.1M13.1×15.4×2.3×n/m19.9%
VCELVericel$2.1B88.1×157×6.8×+23%7.9%
PLXProtalix BioTherapeutics$206.3M11.1×33.6×2.6×+30%23.5%
ADMAAdma Biologics$2.5B15.8×21.3×4.8×+8%33.0%
Peer median$1.5B14.5×27.5×3.7×+23%21.7%

More on Scinai Immunotherapeutics

Each number over time

Its groups

About

Industry
Biotechnology
Sector
Healthcare

Valuation data, not investment advice. Prices as of .